The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
Aimee Ginsburg Arlen
No relevant relationships to disclose
Thomas H. Cartwright
Consultant or Advisory Role - Amgen; Genentech; Lilly
Honoraria - Amgen; Genentech; Lilly
Lalan S. Wilfong
No relevant relationships to disclose
J. Russell Hoverman
Employment or Leadership Position - Texas Oncology; US Oncology
Consultant or Advisory Role - UnitedHealthcare
Greg C Nelson
No relevant relationships to disclose
Brian Turnwald
No relevant relationships to disclose
Roy A. Beveridge
Employment or Leadership Position - US Oncology
Honoraria - US Oncology